Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
Authors:
Open Access
- 25 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
The increasing incidence of geriatric patients with multiple myeloma has elevated concerns in clinical practice. While the introduction of novel therapeutic agents has substantially improved outcomes in younger patients with myeloma, poorer outcomes remain in older patients. Managing older patients requires a multidisciplinary team approach to consider factors that may influence both treatment selection and outcomes. Aging is associated with remodeling of vital organs, physiological downregulations of basal metabolism, susceptibility to multiple comorbidities with ultimate frailty, thereby contributing to the underrepresentation and exclusion of very old patients from clinical trials. Therefore, timely confirmation of a precise diagnosis is crucial for prompt initiation of treatment if the desired outcome is to be achieved. Adequate and judicious assessment using comprehensive geriatric assessment tools minimizes toxicities and treatment discontinuation. Initiating treatment with combinational therapy requires knowledge of indications and anticipated outcomes, as well as individualized therapy with appropriate dose-adjustment. Individualized therapy based on good clinical acumen and best practices obverts unwanted polypharmacy, preventing iatrogenic harm. This review will therefore address the approaches and challenges faced in managing myeloma in geriatric patients aged 80 years and older, highlighting recommended therapeutic strategies and future prospective regimens.Keywords
Funding Information
- National Natural Science Foundation of China (81172257)
- Changjiang Scholar Program, Ministry of Education
This publication has 128 references indexed in Scilit:
- Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for OutcomeClinical Lymphoma Myeloma and Leukemia, 2013
- CarfilzomibBlood, 2013
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2013
- Guidelines for the diagnosis and management of multiple myeloma 2011British Journal of Haematology, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study GroupAnnals of Oncology, 2009
- Understanding frailtyPostgraduate Medical Journal, 2007
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patientsEuropean Journal of Haematology, 1994